RT @hausmannMD: Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global,…

Social Author Image
https://pbs.twimg.com/profile_images/628370848701902849/_w0uLt8I.jpg
Tweet Author
hausmannMD
Social Author Name
Jonathan Hausmann MD
Tweet Content
Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global, pain, function, and inflammation In patients with nr-AxSpA, secukinumab improved ASAS40 through week 52, compared to placebo Dr. Deodhar #ACR19 @RheumNow https://t.co/yLwt47w2wr
Show on Archive Page
On
Display in Search Results
On

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×